We are actively recruiting patients and/or healthy volunteers to participate in clinical trials to evaluate our therapeutic candidates. If you believe you or someone you know might be a good candidate for our trials, we encourage you to reach out directly through the link below.


Pipeline has initiated dosing in a healthy volunteer study for PIPE-791. The goal of this trial is to characterize the safety, tolerability and pharmacokinetic profile of PIPE-791 in healthy volunteers, and to inform dose selection in future clinical studies.  This study will be conducted in three parts: Part 1 will be a Single Ascending Dose (SAD), Part 2 will be a Multiple Ascending Dose (MAD), and Part 3 will be a selected SAD cohort in a fed state. Pipeline expects to enroll up to 80 healthy volunteer subjects in this study with enrollment targeted to be completed by the end of 2023.

For more information on our clinical trials, please visit ClinicalTrials.gov.


PIPE-307 has completed multiple Phase 1 studies of PIPE-307 in healthy patients, including a single- and multiple-ascending dose study to evaluate safety and pharmacokinetics, and a PET study to determine the occupancy of brain M1 after a single dose of PIPE-307 in healthy volunteers. In these studies, PIPE-307 demonstrated linear pharmacokinetic (PK) data consistent with preclinical modeling and was generally well tolerated across all dose cohorts. Importantly, analysis of a battery of neuropsychological measures, including tests involving psychomotor, attention, learning, and executive function, were administered in the Phase 1 study and showed no significant PK or dose related effects on cognitive function.

For more information on our clinical trials, please visit ClinicalTrials.gov.

Reach Out to Us

For questions or comments, please reach out to us directly at info@pipelinetx.com